Who is the CEO of Alteogen?

According to the DART company overview, Alteogen's representative director is 전태연 (name as registered in Korean). The company was founded on 2008-05-13.

Where is Alteogen listed?

Alteogen trades on the Korea Exchange KOSDAQ market under the ticker 196170. Its fiscal year ends in December.

Does Alteogen pay a dividend?

Yes. For fiscal 2025, Alteogen paid a cash dividend of ₩371 per common share, a 0.1% yield as stated in its annual report, with a payout ratio of 14.1%.

Does Alteogen have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: Dilution risk (rights offering or CB/BW/EB issue decided in the past 90 days); Turnaround (latest quarter swung to an operating profit from a loss a year earlier); Revenue +30% (latest quarterly revenue up more than 30% year on year); Op. margin 20%+ (operating margin of 20% or more on quarterly revenue of at least ₩5bn). 2 more signals are shown on the page. These are factual flags, not investment advice.

Which companies are in the same industry as Alteogen?

Under the Korean Standard Industrial Classification recorded on DART, Alteogen is grouped with 53 other listed companies in medical & pharmaceutical r&d. The most covered in Korean news over the past 30 days are Qurient, SillaJen and Rznomics.

Alteogen KRX:196170KOSDAQ

알테오젠 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h14

Articles, 7 days52

DART filings, 7 days3

Articles tracked275since Sep 11

In Q2 2026, Alteogen reported revenue of ₩68.9bn, up 269.5% year on year, and operating profit of ₩34.2bn. Alteogen (알테오젠) appeared in 52 Korean news articles and 3 DART filings over the past seven days. Coverage peaked on Oct 26 with 23 articles. The most common catalyst was contracts & orders (5). It was most often mentioned alongside 글로벌테크놀로지, ABL Bio and Peptron.

Filing signals Turnaround Revenue +30% Op. margin 20%+ M&A / stake deal Private placement Dilution risk Screener

Alteogen quarterly results consolidated, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q2 2026	₩68.9bn	+269.5%	₩34.2bn margin 49.6%	₩30.0bn
Q1 2026	₩71.6bn	-14.5%	₩39.3bn margin 54.9%	₩71.3bn
Q4 2025 derived	₩64.5bn	+26.9%	₩19.6bn margin 30.4%	₩74.4bn
Q3 2025	₩49.0bn	+902.3%	₩26.7bn margin 54.4%	₩22.0bn
Q2 2025	₩18.6bn	+52.4%	−₩426m margin −2.3%	−₩34.3bn
Q1 2025	₩83.7bn	+139.8%	₩61.0bn margin 72.9%	₩83.0bn
Q4 2024 derived	₩50.8bn	+127.4%	₩23.0bn margin 45.3%	₩52.4bn
Q3 2024	₩4.9bn	-77.0%	−₩8.2bn margin −166.8%	−₩9.4bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Alteogen top stories 2 weeks, by number of outlets

1
알테오젠 기술 적용 '키트루다 큐렉스', 3분기 매출 79% 급증
4 outlets · 4 articlesFirst report Oct 30 08:54 메디코파마Earnings
2
알테오젠, ESG 평가기관 에코바디스 ‘골드 메달’…전세계 상위 4% 진입
3 outlets · 3 articlesFirst report Oct 21 10:59 더바이오
3
알테오젠, ADC 피하주사 동물실험서 흡수·내약성 개선 확인
2 outlets · 2 articlesFirst report Oct 26 07:55 메디파나뉴스
4
알테오젠, 글로벌 ESG평가기관 에코바디스 '골드 메달' 획득
2 outlets · 2 articlesFirst report Oct 21 14:02 뉴스1글로벌테크놀로지
5
알테오젠, ADC 피하주사 연구결과 발표 ... "빠른 흡수·전신 부작용 완화 기대"
2 outlets · 2 articlesFirst report Oct 26 08:23 한국경제
6
알테오젠, ESMO서 ADC 피하주사 전환 연구 발표
2 outlets · 2 articlesFirst report Oct 26 08:41 뉴스핌

Latest Alteogen news Korean headlines

13:43

알테오젠 기술 적용 MSD 키트루다 SC, 분기 매출 첫 1조원 돌파
코메디닷컴
11:26

알테오젠 파트너사 MSD, ‘키트루다 큐렉스’ 3분기 매출 1.1조원달성
뉴스타운
11:13

알테오젠, 500억원 규모 제3자배정 유상증자 납입 완료…상환전환우선주 17만4066주 발행
CBC뉴스
10:53

알테오젠 "키트루다SC, 3분기 매출 1조원 상회"
뉴시스경제
10:44

토르테라퓨틱스, 알테오젠·리가켐 창업주 투자 유치
비즈워치
10:39

'키트루다 SC' 매출 8.3억달러…알테오젠 기술료 확대
메디파나뉴스
10:26

Featured알테오젠, 뚜렷한 공시 없이 장중 2%대 약세
재경일보
09:00

토르, 시리즈A 1차 투자 유치…‘알테오젠’·‘리가켐바이오 창업주 투자사’ 참여
더바이오LigaChem Biosciences
08:54
Major알테오젠 기술 적용 '키트루다 큐렉스', 3분기 매출 79% 급증
메디코파마Earnings
3 more on this story · 3 outlets
- ‘알테오젠 기술 적용’ 키트루다 큐렉스, 3분기 매출 1조 넘어…전분기比 79%↑조선비즈 · 11:06
- 알테오젠 기술 적용 ‘키트루다 큐렉스’, 분기 매출 첫 1조 돌파서울경제 · 13:38
- 알테오젠, MSD ‘키트루다 큐렉스’ 3분기 매출 1조1000억원이데일리 · 13:46
06:03

"기술은 여러 곳에, 특허권리는 선명하게"…알테오젠의 협상법
히트뉴스
Oct 2915:09

알테오젠 주가, 10월 29일 장중 221,000원 0.90% 하락
중앙이코노미뉴스
Oct 2820:13

[공시] 알테오젠 정정신고서제출요구 ( 2026.10.19. 제출 증권신고서(합병) )
스페셜타임스
Oct 2815:26

알테오젠 주가, 10월 28일 장중 221,000원 1.14% 상승
중앙이코노미뉴스
Oct 2808:18
'엔허투' 유럽서 조기 유방암까지 승인…알테오젠 SC 기술 가치 커지나
이데일리
1 more on this story · 1 outlets
- '엔허투' 유럽서 조기 유방암까지 승인…알테오젠 SC 기술 가치 커지나이데일리 · Oct 28 08:20
Oct 2807:50

[컨콜] 노바티스, 종근당 심방세동 치료약 2상 개발 지속…알테오젠 SC도 확보
더바이오Chong Kun Dang Pharmaceutical
Oct 2807:13

엔허투, 유럽 조기유방암까지 확대…알테오젠 SC는 76명 1상서 별도 검증
메디코파마
Oct 2804:42
[빅데이터로본다] 생물공학 상장기업 2026년 10월 브랜드평판... 1위 알테오젠, 2위 펩트론, 3위 에이비엘바이오
일간투데이Peptron ABL Bio
1 more on this story · 1 outlets
- 생물공학 상장기업 2026년 10월 브랜드평판...알테오젠, 펩트론, 에이비엘바이오 順에너지신문 · Oct 28 10:36
Oct 2715:24

알테오젠 주가, 10월 27일 장중 218,000원 0.23% 하락
중앙이코노미뉴스
Oct 2714:04

연구개발특구진흥재단, 알테오젠·DRB동일과 딥테크 사업화 협력 확대
웹이코노미DRB Holding
Oct 2711:43

엇갈린 바이오 대장주...셀트리온·알테오젠 '웃고' 삼성바이오 '울고'
이코노미스트Celltrion
Oct 2710:25

알테오젠 22만6000원으로 3%대 상승
CBC뉴스
Oct 2708:08

K바이오 한파 속 알테오젠 선방… 하반기에도 이어갈까
아주경제
Oct 2700:00

[심층분석] “외국인·기관 융단폭격에 수급 무너졌다”…삼성전자·알테오젠 등 대형주 집중 매도
더페어뉴스Samsung Electronics
Oct 2616:53

‘바이오 대장주’ 알테오젠, 연구개발특구 파트너 찾는다
디지털타임스
Oct 2616:00

대덕특구, 알테오젠과 바이오 딥테크 오픈이노베이션…협력 기술 모집
머니투데이
Oct 2615:01

알테오젠 ADC SC, 동물서 독성 완화 신호…엔허투 76명 1상서 검증
메디코파마
Oct 2613:49

대덕특구본부-알테오젠, 바이오 분야 R&D·사업화 협력
아시아경제
Oct 2613:23

특구재단, 알테오젠과 바이오 딥테크 기업 '성장 사다리' 놓는다
충청뉴스
Oct 2611:12

알테오젠 주가, 10월 26일 장중 220,000원 2.00% 하락
중앙이코노미뉴스
Oct 2610:43

대덕특구·알테오젠, 3곳 뽑아 공동 R&D·투자연계 등 동반성장 추진
지디넷코리아

Articles per day 2 weeks

217

118

319

520

1221

522

124

2326

627

828

129

1330

Company profile

CEO: 전태연
Industry: Medical & pharmaceutical R&D
Founded: 2008-05-13
Fiscal year-end: December
Head office: 대전광역시 유성구
Website: alteogen.com
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

Alteogen dividends annual report

Korea dividend rankings

Year	Per share	Yield	Payout
FY2025	₩371	0.1%	14.1%
FY2024	–	–	–
FY2023	–	–	–

Same industry Medical & pharmaceutical R&D

All in industry

Company	Latest quarter op. profit	Articles 30d
Qurient	−₩12.8bn	74
SillaJen	−₩6.2bn	51
Rznomics	−₩6.9bn	47
LigaChem Biosciences	−₩72.0bn	43
OliX Pharmaceuticals	−₩14.0bn	36
D&D Pharmatech	−₩9.9bn	34
GI Innovation	−₩14.4bn	33
Dt&cro	−₩6.6bn	25

Compare Alteogen side by side with these companies

Alteogen DART filings

11:11

Other 증권발행결과(자율공시)
Other
11:09

Other 증권발행결과(자율공시)
Other
Oct 2820:01

Other 정정신고서제출요구( 2026.10.19. 제출 증권신고서(합병) )
Other
Oct 1917:25

Other [기재정정]증권신고서(합병)
Other
Oct 1416:54

Other 증권발행결과(자율공시)
Other
Oct 1416:53

Other 증권발행결과(자율공시)
Other
Oct 1411:04

Other 증권신고서(합병)
Other
Oct 816:12

Investor relations event 기업설명회(IR)개최
Other
Oct 617:51

Other 주주명부폐쇄기간또는기준일설정
Other
Oct 617:42

Merger / spin-off 회사합병결정(종속회사의주요경영사항)
Capital & M&A
Oct 617:36

Merger / spin-off 주요사항보고서(회사합병결정)
Capital & M&A
Oct 616:18

Rights offering 주요사항보고서(유상증자결정)
Capital & M&A

Catalysts 2 weeks

Contracts & orders5
Tech & capacity3
Earnings2
Clinical & approvals1

Mentioned alongside 2 weeks

Alteogen FAQ

Who is the CEO of Alteogen?: According to the DART company overview, Alteogen's representative director is 전태연 (name as registered in Korean). The company was founded on 2008-05-13.
Where is Alteogen listed?: Alteogen trades on the Korea Exchange KOSDAQ market under the ticker 196170. Its fiscal year ends in December.
What were Alteogen's latest quarterly results?: In Q2 2026, Alteogen reported revenue of ₩68.9bn, up 269.5% year on year, and operating profit of ₩34.2bn. Figures come from reports filed on DART.
Does Alteogen pay a dividend?: Yes. For fiscal 2025, Alteogen paid a cash dividend of ₩371 per common share, a 0.1% yield as stated in its annual report, with a payout ratio of 14.1%.
Does Alteogen have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: Dilution risk (rights offering or CB/BW/EB issue decided in the past 90 days); Turnaround (latest quarter swung to an operating profit from a loss a year earlier); Revenue +30% (latest quarterly revenue up more than 30% year on year); Op. margin 20%+ (operating margin of 20% or more on quarterly revenue of at least ₩5bn). 2 more signals are shown on the page. These are factual flags, not investment advice.
Which companies are in the same industry as Alteogen?: Under the Korean Standard Industrial Classification recorded on DART, Alteogen is grouped with 53 other listed companies in medical & pharmaceutical r&d. The most covered in Korean news over the past 30 days are Qurient, SillaJen and Rznomics.